NCT06769126RecruitingPhase 2
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- First submitted
- 2 Jan 2025
- Start date
- 6 Nov 2025
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- SWOG Cancer Research Network
- Diseases
- Lung cancer
- NCT number
- NCT06769126
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 900
- From 6 Nov 2025 to the primary completion date, 31 Dec 2028
- 148 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have a history of limited stage small cell lung cancer
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must meet 1 of the following criteria prior to step 1:
- Treatment naïve and planning to receive frontline induction treatment with platinum plus etoposide in combination with durvalumab, OR,
- Have initiated frontline induction therapy and completed at least 1 (≥ 1) cycle and at most 3 (≤ 3) cycles of platinum and etoposide. At most 2 (≤ 2) of these cycles could have been given without durvalumab
- NOTE: Participants must not have received immunotherapy other than durvalumab (e.g., atezolizumab) prior to enrollment
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have received any anti PD-1 or anti PD-L1 (including durvalumab \[MEDI4736\]) treatment for SCLC prior to starting frontline induction treatment for ES-SCLC
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have received anti PD-1 or anti PD-L1 other than durvalumab (MEDI4736) as part of frontline induction treatment for ES-SCLC. Participants must have not received atezolizumab, pembrolizumab, or nivolumab as part of frontline induction treatment
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have received any investigational agent for the treatment of ES-SCLC
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for SCLC treatment while receiving treatment on this study
- NOTE: If participant has bone metastases, bisphosphonates are allowed
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have any unresolved toxicity National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade ≥ 2 from previous anticancer therapy with the exception of alopecia, and vitiligo
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must be ≥ 18 years old at the time of step 1 registration
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must be able to safely receive the frontline induction treatment with platinum plus etoposide in combination with durvalumab, per the current Food and Drug Administration (FDA)-approved package insert(s), institutional guidelines, and the treating investigator's discretion
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must have Zubrod performance status of 0-2 within 28 days prior to step 1 registration
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must have fully recovered from the effects of prior surgery in the opinion of the treating investigator within 28 days prior to step 1 registration
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have had an allogenic organ transplantation
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: Participants must have adequate tumor tissue available from SCLC and agree to have these tissue specimens submitted. Participants must agree to have any leftover tissue (tissue that remains after subtype and biomarker testing) retained for the use of future correlative studies.
- NOTE: After a participant has been registered to step 1 registration, the tissue must be submitted to BostonGene. Sites will receive a notification from the Southwest Oncology Group (SWOG) Statistics and Data Management Center within 19 days after tissue submission. Patients must not be registered to step 2 prior to receiving notification of cohort assignment
- NOTE: A histologic review will be performed to confirm adequate cellularity for the testing. If inadequate cellularity, additional archival unstained slides from the same participant may be submitted if it does not exceed the window of starting maintenance therapy
- STEP 1: SCREENING AND INDUCTION TREATMENT REGISTRATION: NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Site must have received notification from the SWOG Statistics and Data Management Center (SDMC) of the participant's SLFN11 testing results and have been determined to have subtype A, N, I, or P: confirmed by BostonGene and assigned to a cohort
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants may have measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and must have their disease assessed by CT of chest/abdomen/pelvis (with contrast unless contraindicated) within 28 days prior to step 2 for measurable disease or within 42 days prior to step 2 for non-measurable disease. All known sites of disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1). Any lesions assessed using a non-diagnostic PET/CT of chest/abdomen/pelvis will be considered non-measurable lesions
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to step 2 randomization. Participant must not have leptomeningeal disease, spinal cord compression, or symptomatic brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment, and prior to step 2 randomization, AND (2) participant has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to step 2 randomization
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants with untreated brain metastases must be asymptomatic and stable off steroids prior to step 2 randomization.
- NOTE: Exceptions to corticosteroid criterion are: (1) intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection), (2) systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent, or (3) steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). Premedication with steroids for chemotherapy is acceptable
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must not have experienced disease progression in the opinion of treating investigator during induction treatment and prior to step 2
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have completed frontline induction therapy. Induction therapy must have included 4-6 cycles of platinum plus etoposide and 4 cycles of durvalumab (MEDI4736); at most 2 (≤ 2) cycles of platinum plus etoposide may have been given without durvalumab (MEDI4736). Durvalumab (MEDI4736) must have been given in combination with platinum plus etoposide
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants who received consolidation thoracic radiation therapy must have completed all radiation therapy at least 14 days prior to step 2
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: For participants not receiving consolidation thoracic radiation, step 2 registration must occur at least 3 weeks but not more than 6 weeks after the last dose of frontline induction therapy (platinum plus etoposide in combination with durvalumab \[MEDI4736\])
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: For participants receiving consolidation thoracic radiation after induction therapy, step 2 registration must occur at least 3 weeks but no more than 8 weeks after the last dose of frontline induction therapy (platinum plus etoposide in combination with durvalumab \[MEDI4736\])
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must not have received atezolizumab, pembrolizumab, or nivolumab as part of their frontline induction treatment. Participants must not have received prophylactic cranial irradiation (PCI)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have a complete medical history and physical within 28 days prior to step 2
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have body weight \> 30 kg
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have Zubrod performance status of 0-2 within 28 days prior to step 2
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Hemoglobin \> 9.0 g/dL (within 28 days prior to step 2)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Absolute neutrophil count ≥ 1.5 x 10\^3/uL (within 28 days prior to step 2)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Platelets ≥ 100 x 10\^3/uL (within 28 days prior to step 2)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Total bilirubin ≤ institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to step 2)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤ 5 × institutional ULN (within 28 days prior to step 2)
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must have creatinine ≤ 1.5x the institutional upper limit of normal (IULN) OR measured OR calculated creatinine clearance ≥ 45 mL/min using the following Cockcroft-Gault Formula For creatinine clearance formula see the tools on the Cancer Research and Biostatistics (CRA) Workbench https://txwb.crab.org/TXWB/Tools.aspx
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants with a known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to step 2 registration
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants with a known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to randomization, if indicated
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured or currently be receiving treatment for HVC. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must not have experienced the following during induction treatment: Any grade 3 or worse immune-mediated adverse event (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved grade 2 irAE, nor have experienced a toxicity that led to permanent discontinuation of prior durvalumab (MEDI4736). Toxicity of any grade that requires replacement therapy and has stabilized on therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must not have received a live or live attenuated vaccine within 30 days prior to step 2. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever rabies, Bacillus Calmette-Guerin (BCG) and typhoid vaccine. Seasonal influenza vaccines and COVID-19 vaccines are allowed, however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated, and are not allowed
- STEP 2: COHORT REGISTRATION AND MAINTENANCE RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (148)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McFarland Clinic - Ames Coordinator of this site? Confirm its status | Ames | United States | Recruiting |
| Mary Greeley Medical Center Coordinator of this site? Confirm its status | Ames | United States | Recruiting |
| Community Hospital of Anaconda Coordinator of this site? Confirm its status | Anaconda | United States | Recruiting |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Coordinator of this site? Confirm its status | Ankeny | United States | Recruiting |
| Duluth Clinic Ashland Coordinator of this site? Confirm its status | Ashland | United States | Recruiting |
| UCHealth University of Colorado Hospital Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
| University of Maryland/Greenebaum Cancer Center Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| Sanford Joe Lueken Cancer Center Coordinator of this site? Confirm its status | Bemidji | United States | Recruiting |
| Billings Clinic Cancer Center Coordinator of this site? Confirm its status | Billings | United States | Recruiting |
| Sanford Bismarck Medical Center Coordinator of this site? Confirm its status | Bismarck | United States | Recruiting |
| Saint Joseph's/Candler - Bluffton Campus Coordinator of this site? Confirm its status | Bluffton | United States | Recruiting |
| Prisma Health Cancer Institute - Spartanburg Coordinator of this site? Confirm its status | Boiling Springs | United States | Recruiting |
| McFarland Clinic - Boone Coordinator of this site? Confirm its status | Boone | United States | Suspended |
| Tufts Medical Center Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Bozeman Health Deaconess Hospital Coordinator of this site? Confirm its status | Bozeman | United States | Recruiting |
| Essentia Health Saint Joseph's Medical Center Coordinator of this site? Confirm its status | Brainerd | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton Coordinator of this site? Confirm its status | Brighton | United States | Recruiting |
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
| Lahey Hospital and Medical Center Coordinator of this site? Confirm its status | Burlington | United States | Recruiting |
| Aultman Health Foundation Coordinator of this site? Confirm its status | Canton | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Canton Coordinator of this site? Confirm its status | Canton | United States | Recruiting |
| Mercy Hospital Coordinator of this site? Confirm its status | Cedar Rapids | United States | Recruiting |
| Oncology Associates at Mercy Medical Center Coordinator of this site? Confirm its status | Cedar Rapids | United States | Recruiting |
| Miami Valley Hospital South Coordinator of this site? Confirm its status | Centerville | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Coordinator of this site? Confirm its status | Chelsea | United States | Recruiting |
| Northwestern University Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Coordinator of this site? Confirm its status | Clive | United States | Recruiting |
| Kootenai Health - Coeur d'Alene Coordinator of this site? Confirm its status | Coeur d'Alene | United States | Recruiting |
| Memorial Hospital North Coordinator of this site? Confirm its status | Colorado Springs | United States | Recruiting |
| UCHealth Memorial Hospital Central Coordinator of this site? Confirm its status | Colorado Springs | United States | Recruiting |
| Mercy Hospital Coordinator of this site? Confirm its status | Coon Rapids | United States | Recruiting |
| Baptist Health Corbin Coordinator of this site? Confirm its status | Corbin | United States | Recruiting |
| Premier Blood and Cancer Center Coordinator of this site? Confirm its status | Dayton | United States | Recruiting |
| Miami Valley Hospital Coordinator of this site? Confirm its status | Dayton | United States | Recruiting |
| Miami Valley Hospital North Coordinator of this site? Confirm its status | Dayton | United States | Recruiting |
| Essentia Health - Deer River Clinic Coordinator of this site? Confirm its status | Deer River | United States | Recruiting |
| Northwestern Medicine Cancer Center Kishwaukee Coordinator of this site? Confirm its status | DeKalb | United States | Recruiting |
| Smilow Cancer Hospital-Derby Care Center Coordinator of this site? Confirm its status | Derby | United States | Recruiting |
| Iowa Methodist Medical Center Coordinator of this site? Confirm its status | Des Moines | United States | Recruiting |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Coordinator of this site? Confirm its status | Des Moines | United States | Recruiting |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Coordinator of this site? Confirm its status | Des Moines | United States | Recruiting |
| Mercy Medical Center - Des Moines Coordinator of this site? Confirm its status | Des Moines | United States | Recruiting |
| Henry Ford Health Saint John Hospital Coordinator of this site? Confirm its status | Detroit | United States | Recruiting |
| Essentia Health Cancer Center Coordinator of this site? Confirm its status | Duluth | United States | Recruiting |
| Prisma Health Cancer Institute - Easley Coordinator of this site? Confirm its status | Easley | United States | Recruiting |
| Henry Ford River District Hospital Coordinator of this site? Confirm its status | East China Township | United States | Recruiting |
| Fairview Southdale Hospital Coordinator of this site? Confirm its status | Edina | United States | Recruiting |
| Smilow Cancer Hospital Care Center-Fairfield Coordinator of this site? Confirm its status | Fairfield | United States | Recruiting |
| University of Kansas Clinical Research Center Coordinator of this site? Confirm its status | Fairway | United States | Recruiting |
| Sanford Roger Maris Cancer Center Coordinator of this site? Confirm its status | Fargo | United States | Recruiting |
| Sanford Broadway Medical Center Coordinator of this site? Confirm its status | Fargo | United States | Recruiting |
| Essentia Health Cancer Center-South University Clinic Coordinator of this site? Confirm its status | Fargo | United States | Recruiting |
| Cancer Care and Hematology-Fort Collins Coordinator of this site? Confirm its status | Fort Collins | United States | Recruiting |
| Poudre Valley Hospital Coordinator of this site? Confirm its status | Fort Collins | United States | Recruiting |
| McFarland Clinic - Trinity Cancer Center Coordinator of this site? Confirm its status | Fort Dodge | United States | Recruiting |
| Atrium Medical Center-Middletown Regional Hospital Coordinator of this site? Confirm its status | Franklin | United States | Recruiting |
| Northwestern Medicine Cancer Center Delnor Coordinator of this site? Confirm its status | Geneva | United States | Recruiting |
| Tidelands Georgetown Memorial Hospital Coordinator of this site? Confirm its status | Georgetown | United States | Recruiting |
| Northwestern Medicine Glenview Outpatient Center Coordinator of this site? Confirm its status | Glenview | United States | Recruiting |
| Lutheran Hospital - Cancer Centers of Colorado Coordinator of this site? Confirm its status | Golden | United States | Recruiting |
| Northwestern Medicine Grayslake Outpatient Center Coordinator of this site? Confirm its status | Grayslake | United States | Recruiting |
| Benefis Sletten Cancer Institute Coordinator of this site? Confirm its status | Great Falls | United States | Recruiting |
| UCHealth Greeley Hospital Coordinator of this site? Confirm its status | Greeley | United States | Recruiting |
| Prisma Health Cancer Institute - Eastside Coordinator of this site? Confirm its status | Greenville | United States | Recruiting |
| Prisma Health Cancer Institute - Faris Coordinator of this site? Confirm its status | Greenville | United States | Recruiting |
| Prisma Health Cancer Institute - Butternut Coordinator of this site? Confirm its status | Greenville | United States | Recruiting |
| Miami Valley Cancer Care and Infusion Coordinator of this site? Confirm its status | Greenville | United States | Recruiting |
| Prisma Health Cancer Institute - Greer Coordinator of this site? Confirm its status | Greer | United States | Recruiting |
| Henry Ford Saint John Hospital - Van Elslander Coordinator of this site? Confirm its status | Grosse Pointe Woods | United States | Recruiting |
| Henry Ford Saint John Hospital - Breast Coordinator of this site? Confirm its status | Grosse Pointe Woods | United States | Recruiting |
| Henry Ford Saint John Hospital - Academic Coordinator of this site? Confirm its status | Grosse Pointe Woods | United States | Recruiting |
| Smilow Cancer Hospital Care Center - Guilford Coordinator of this site? Confirm its status | Guilford | United States | Recruiting |
| Essentia Health Hibbing Clinic Coordinator of this site? Confirm its status | Hibbing | United States | Recruiting |
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| McFarland Clinic - Jefferson Coordinator of this site? Confirm its status | Jefferson | United States | Suspended |
| University of Kansas Cancer Center - Briarcliff Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| University of Kansas Cancer Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| University of Kansas Cancer Center - North Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| Gundersen Lutheran Medical Center Coordinator of this site? Confirm its status | La Crosse | United States | Recruiting |
| Northwestern Medicine Lake Forest Hospital Coordinator of this site? Confirm its status | Lake Forest | United States | Recruiting |
| University of Michigan Health - Sparrow Lansing Coordinator of this site? Confirm its status | Lansing | United States | Recruiting |
| University of Kansas Cancer Center - Lee's Summit Coordinator of this site? Confirm its status | Lee's Summit | United States | Recruiting |
| Baptist Health Lexington Coordinator of this site? Confirm its status | Lexington | United States | Recruiting |
| Baptist Health Hamburg Coordinator of this site? Confirm its status | Lexington | United States | Recruiting |
| Trinity Health Saint Mary Mercy Livonia Hospital Coordinator of this site? Confirm its status | Livonia | United States | Recruiting |
| Loma Linda University Medical Center Coordinator of this site? Confirm its status | Loma Linda | United States | Recruiting |
| Medical Center of the Rockies Coordinator of this site? Confirm its status | Loveland | United States | Recruiting |
| Henry Ford Warren Hospital - Breast Macomb Coordinator of this site? Confirm its status | Macomb | United States | Recruiting |
| Henry Ford Saint John Hospital - Macomb Medical Coordinator of this site? Confirm its status | Macomb | United States | Recruiting |
| Saint John's Hospital - Healtheast Coordinator of this site? Confirm its status | Maplewood | United States | Recruiting |
| McFarland Clinic - Marshalltown Coordinator of this site? Confirm its status | Marshalltown | United States | Recruiting |
| Loyola University Medical Center Coordinator of this site? Confirm its status | Maywood | United States | Recruiting |
| Abbott-Northwestern Hospital Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
| Hennepin County Medical Center Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
| Community Medical Center Coordinator of this site? Confirm its status | Missoula | United States | Recruiting |
| Saint Alphonsus Cancer Care Center-Nampa Coordinator of this site? Confirm its status | Nampa | United States | Recruiting |
| Medical Oncology Hematology Consultants PA Coordinator of this site? Confirm its status | Newark | United States | Recruiting |
| Helen F Graham Cancer Center Coordinator of this site? Confirm its status | Newark | United States | Recruiting |
| Providence Newberg Medical Center Coordinator of this site? Confirm its status | Newberg | United States | Recruiting |
| Yale University Coordinator of this site? Confirm its status | New Haven | United States | Recruiting |
| New Ulm Medical Center Coordinator of this site? Confirm its status | New Ulm | United States | Recruiting |
| Yale-New Haven Hospital North Haven Medical Center Coordinator of this site? Confirm its status | North Haven | United States | Recruiting |
| Northwestern Medicine Oak Brook Coordinator of this site? Confirm its status | Oak Brook | United States | Recruiting |
| University of Oklahoma Health Sciences Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
| The University of Kansas Cancer Center - Olathe Coordinator of this site? Confirm its status | Olathe | United States | Recruiting |
| Providence Willamette Falls Medical Center Coordinator of this site? Confirm its status | Oregon City | United States | Recruiting |
| Northwestern Medicine Orland Park Coordinator of this site? Confirm its status | Orland Park | United States | Recruiting |
| University of Kansas Cancer Center-Overland Park Coordinator of this site? Confirm its status | Overland Park | United States | Recruiting |
| Lahey Medical Center-Peabody Coordinator of this site? Confirm its status | Peabody | United States | Recruiting |
| FirstHealth of the Carolinas-Moore Regional Hospital Coordinator of this site? Confirm its status | Pinehurst | United States | Recruiting |
| Trinity Health Saint Joseph Mercy Oakland Hospital Coordinator of this site? Confirm its status | Pontiac | United States | Recruiting |
| Providence Portland Medical Center Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Providence Saint Vincent Medical Center Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Kootenai Clinic Cancer Services - Post Falls Coordinator of this site? Confirm its status | Post Falls | United States | Recruiting |
| Eisenhower Medical Center Coordinator of this site? Confirm its status | Rancho Mirage | United States | Recruiting |
| VCU Massey Comprehensive Cancer Center Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| VCU Massey Cancer Center at Stony Point Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| University of Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
| University of California Davis Comprehensive Cancer Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
| Park Nicollet Clinic - Saint Louis Park Coordinator of this site? Confirm its status | Saint Louis Park | United States | Recruiting |
| United Hospital Coordinator of this site? Confirm its status | Saint Paul | United States | Recruiting |
| Regions Hospital Coordinator of this site? Confirm its status | Saint Paul | United States | Recruiting |
| Salina Regional Health Center Coordinator of this site? Confirm its status | Salina | United States | Recruiting |
| Kootenai Clinic Cancer Services - Sandpoint Coordinator of this site? Confirm its status | Sandpoint | United States | Recruiting |
| Essentia Health Sandstone Coordinator of this site? Confirm its status | Sandstone | United States | Recruiting |
| Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Coordinator of this site? Confirm its status | Savannah | United States | Recruiting |
| Prisma Health Cancer Institute - Seneca Coordinator of this site? Confirm its status | Seneca | United States | Recruiting |
| Sanford Cancer Center Oncology Clinic Coordinator of this site? Confirm its status | Sioux Falls | United States | Recruiting |
| Sanford USD Medical Center - Sioux Falls Coordinator of this site? Confirm its status | Sioux Falls | United States | Recruiting |
| VCU Community Memorial Health Center Coordinator of this site? Confirm its status | South Hill | United States | Recruiting |
| Mercy Hospital South Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Mercy Hospital Saint Louis Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| VCU Health Tappahannock Hospital Coordinator of this site? Confirm its status | Tappahannock | United States | Recruiting |
| Smilow Cancer Hospital-Torrington Care Center Coordinator of this site? Confirm its status | Torrington | United States | Recruiting |
| Upper Valley Medical Center Coordinator of this site? Confirm its status | Troy | United States | Recruiting |
| Smilow Cancer Hospital Care Center-Trumbull Coordinator of this site? Confirm its status | Trumbull | United States | Recruiting |
| Essentia Health Virginia Clinic Coordinator of this site? Confirm its status | Virginia | United States | Recruiting |
| Henry Ford Madison Heights Hospital - Breast Coordinator of this site? Confirm its status | Warren | United States | Recruiting |
| Henry Ford Health Warren Hospital Coordinator of this site? Confirm its status | Warren | United States | Recruiting |
| Henry Ford Warren Hospital - GLCMS Coordinator of this site? Confirm its status | Warren | United States | Recruiting |
| Northwestern Medicine Cancer Center Warrenville Coordinator of this site? Confirm its status | Warrenville | United States | Recruiting |
| Smilow Cancer Hospital-Waterbury Care Center Coordinator of this site? Confirm its status | Waterbury | United States | Recruiting |
| Smilow Cancer Hospital Care Center - Waterford Coordinator of this site? Confirm its status | Waterford | United States | Recruiting |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Coordinator of this site? Confirm its status | Waukee | United States | Recruiting |
| Wilmot Cancer Institute at Webster Coordinator of this site? Confirm its status | Webster | United States | Recruiting |
| The Iowa Clinic PC Coordinator of this site? Confirm its status | West Des Moines | United States | Recruiting |
| University of Kansas Hospital-Westwood Cancer Center Coordinator of this site? Confirm its status | Westwood | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Coordinator of this site? Confirm its status | Ypsilanti | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.